Table 2. Pemetrexed for the treatment of BMs from NSCLC.
| Author (Ref.) | Regimen | Study design | Histology | Prior radiation | Prior chemotherapy | No. of patients | IRR (%) | mOS (months) |
|---|---|---|---|---|---|---|---|---|
| Bearz et al. (49) | Pemetrexed | Retrospective | NSCLC | Heterogeneous | Yes | 39 | 38.4 | 10 |
| Barlesi et al. (50) | Pemetrexed/cisplatin | Phase 2 | 93% NSq NSCLC | No | No | 43 | 41.9 | 7.4 |
| Bailon et al. (51) | Pemetrexed/carboplatin | Observational | Adenocarcinoma | No | No | 30 | 40 | 9.7 |
| Dinglin et al. (52) | Pemetrexed/cisplatin | Phase 2 | Adenocarcinoma | Concurrent WBRT | No | 42 | 68.3 | 12.6 |
BMs, brain metastases; NSCLC, non-small cell lung cancer; IRR, intracranial response rate; mOS, median overall survival; NSq, non-squamous; WBRT, whole brain radiotherapy.